Foscarnet for suppression of human immunodeficiency virus replication
Open Access
- 1 March 1994
- journal article
- clinical trial
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 38 (3) , 604-607
- https://doi.org/10.1128/aac.38.3.604
Abstract
The effect of foscarnet against human immunodeficiency virus (HIV) was evaluated in nine HIV-infected individuals; six completed 28 days of induction therapy. The overall mean increase in CD4+ lymphocytes was 64 cells per mm3. The mean decline in the HIV antigen concentration was 108 pg/ml (P = 0.03), and suppression was related to systemic foscarnet exposure by a maximum-effect pharmacodynamic model.Keywords
This publication has 13 references indexed in Scilit:
- Pharmacokinetics of concomitantly administered foscarnet and zidovudine for treatment of human immunodeficiency virus infection (AIDS Clinical Trials Group protocol 053)Antimicrobial Agents and Chemotherapy, 1992
- A Randomized, Controlled Trial of Foscarnet in the Treatment of Cytomegalovirus Retinitis in Patients with AIDSAnnals of Internal Medicine, 1991
- Pharmacokinetics of foscarnet and distribution to cerebrospinal fluid after intravenous infusion in patients with human immunodeficiency virus infectionAntimicrobial Agents and Chemotherapy, 1989
- Pharmacokinetics of intermittently administered intravenous foscarnet in the treatment of acquired immunodeficiency syndrome patients with serious cytomegalovirus retinitisAntimicrobial Agents and Chemotherapy, 1989
- Inhibition of human immunodeficiency virus in vitro by combinations of 3'-azido-3'-deoxythymidine and foscarnetAntimicrobial Agents and Chemotherapy, 1989
- Determination of phosphonoformate (foscarnet) in biological fluids by ion-pair reversed-phase liquid chromatographyJournal of Chromatography B: Biomedical Sciences and Applications, 1989
- Simulation of linear compartment models with application to nuclear medicine kinetic modelingComputer Methods and Programs in Biomedicine, 1988
- INHIBITION OF HUMAN T-CELL LYMPHOTROPIC VIRUS TYPE III IN VITRO BY PHOSPHONOFORMATEThe Lancet, 1985
- Understanding the Dose-Effect RelationshipClinical Pharmacokinetics, 1981
- Forecasting individual pharmacokineticsClinical Pharmacology & Therapeutics, 1979